Fecal microbiota profiles as a diagnostic biomarkers in cirrhosis and hepatocellular carcinoma and the impact of life style and nutrition 
EASL LiverTree™, Michal Safran, 207342
Gut microbes mediate liver fibrosis in chimeric mice with human hepatocytes persistently infected with hepatitis B virus
EASL LiverTree™, Masaya Sugiyama, 207343
Serum CXCL14 chemokine as a biomarker during murine acute and chronic hepatitis
EASL LiverTree™, Christelle Devisme, 207358
Autophagy-related liver enzymes in chronic liver disease
EASL LiverTree™, Dimitrios Samonakis, 207359
Clinical presentation, natural history and treatment of hepatic sarcoidosis: a case-series of 39 patients with histologically proven hepatic sarcoidosis
EASL LiverTree™, Malte Wehmeyer, 207361
The effect of re-exposure to somatostatin analogues in patients with polycystic liver disease
EASL LiverTree™, René van Aerts, 207375
The PR interval in the fetal electrocardiogram is significantly prolonged in severe Intrahepatic Cholestasis of Pregnancy and potentially normalised by UDCA therapy
EASL LiverTree™, Tharni Vasavan, 207376
DIFFERENTIALDIAGNOSTICS OF CONGENITAL CHOLESTATIC DISEASES IN CHILDREN OF EARLY AGE 
EASL LiverTree™, Galina Volynets, 207377
Characteristics associated with non-response to ursodeoxycholic acid in primary biliary cholangitis
EASL LiverTree™, Teresa Dias, 207394
Evaluation of the New criteria in the diagnosis of cystic fibrosis liver disease
EASL LiverTree™, Iliana Mani, 207395
Prognostic Value of 2D-Shear Wave Elastography(2D-SWE) for staging cirrhosis in chronic liver diseases (CLD) in two severity classes according to liver-related complications
EASL LiverTree™, Priscila Pollo Flores, 207397
Correlation between controlled attenuationparameter assessed with Fibroscan and steatosis percent objectively quantifiedfrom the entire liver biopsy specimen using a computer analysis tool. Preliminary results.
EASL LiverTree™, Monica Platon Lupsor, 207412
Performance of shear-wave elastography to detect high-risk esophageal varices in cirrhosis is improved by spleen stiffness estimation
EASL LiverTree™, Seong Hee Kang, 207413
Non-invasive estimation of hepatic fibrosis and steatosis: comparison of 2D shear-wave elastography and acoustic structure quantification with transient elastography and controlled attenuation parameter
EASL LiverTree™, Valentin Blank, 207414
CT-driven Model for End-Stage Liver Disease: Comparison of Survival Prediction with MELD score
EASL LiverTree™, Ji Eun Lee, 207415
Distribution and changes of FIB-4 index in normal health checkup examinees
EASL LiverTree™, Shuhei Hige, 207430
Which is the chance for type 2 diabetes patients to develop severe liver disease?
EASL LiverTree™, Ioan Sporea, 207431
Intelligent Liver Function diagnostic pathway - Relevance of alanine transaminase normal values.
EASL LiverTree™, Emma Robinson, 207432
Phenotypic characteristics and improvement of liver stiffness measurement during follow-up in patients with Wilson's disease
EASL LiverTree™, Razvan Iacob, 207435
ADAR-mediated A-to-I RNA Editing in Human Hepatocelluar Carcinoma
EASL LiverTree™, Guangqi Song, 207451
Sulfatase 2 Antagonizes Starvation-Induced Autophagy in Hepatocellular Carcinoma
EASL LiverTree™, Paola Alejandra Romecin Duran, 207452
In vivo knockdown of Plk1 using a novel breakable mesoporous silica particle siRNA carrier reduces tumor growth in an orthotopic xenograft mouse model of hepatocellular carcinoma
EASL LiverTree™, Antonio Saviano, 207453
CeO2NPs ARE SIMILARLY EFECTIVE AS SORAFENIB IN INCREASING SURVIVAL IN RATS WITH HCC
EASL LiverTree™, Guillermo Fernández Varo, 207454
Quantitative comparison of PD-L1 immuno-histochemical assays in hepatocellular carcinoma: the Blueprint-HCC study.
EASL LiverTree™, David James Pinato, 207468
Circulating exosomal non-coding RNAs as prognostic biomarkers in human hepatocellular carcinoma
EASL LiverTree™, Yu Rim Lee, 207470
Molecular characterization of autophagic and apoptotic signaling induced by Sorafenib in liver cancer cells: In vitro and in vivo studies
EASL LiverTree™, M. Ángeles Rodríguez-Hernández, 207472
Sensitization of cholangiocarcinoma to chemotherapy by SOX17-induced down-regulation of drug export pumps ABCC3 and AGCG2
EASL LiverTree™, Rocio Macias, 207488
Defective NKp30-mediated function in hepatocellular carcinoma-infiltrating NK cells
EASL LiverTree™, STEFANIA MANTOVANI, 207489
Cost-effective target sequencing panel for hepatocellular carcinoma mutational screening
EASL LiverTree™, Charlotte Ng, 207490
Sorafenib/Regorafenib resistance and BH3-mimetics efficacy in hepatocellular carcinoma treatment is determined by mitochondrial changes in the BCL-2 profile.
EASL LiverTree™, Tutusaus Anna, 207505
MALDI IMAGING OF HEPATOCHOLANGIOCARCINOMAS: A CLUE TO TACKLE TUMOR HETEROGENEITY. PRELIMINARY RESULTS
EASL LiverTree™, Elia Gigante, 207506
Aspecific ECM composition regulates Smad dependent - TGFbeta1-induced EMT response in HepG2 cells engineered in cirrhotic and healthyliver 3D scaffolds
EASL LiverTree™, Krista Rombouts, 207508
Analysis of HBV DNA Integration in Tumor and non-Tumor Liver Tissues by a High-Throughput Viral Integration Detection Method.
EASL LiverTree™, Deborah D'Aliberti, 207509
Prevalence and resistance rates of infections with enterococci in patients with cirrhosis
EASL LiverTree™, Theresa Bucsics, 207523
The area of the paarspinal muscle mass in patients with cirrhosis although not different from controls predicts cirrhosis-associated complications and death in a large mono-centric study
EASL LiverTree™, Cornelius Engelmann, 207526
TLR9-mediated immune sensing of bacterial DNA in decompensated cirrhosis is stage-dependent
EASL LiverTree™, Eihab Al-Herwi, 207527
The role of HbA1c as a risk factor for the development of spontaneous bacterial peritonitis in patients with decompensated liver cirrhosis
EASL LiverTree™, Tammo Lambert Tergast, 207540
Antibiotic-Associated Disruption of Microbial Composition and Functionality is Restored after Fecal Transplant in Cirrhosis
EASL LiverTree™, Jasmohan S Bajaj, 207541
Beta-Blocker use in Cirrhosis is Independently Associated with Minimal Hepatic Encephalopathy
EASL LiverTree™, Jasmohan S Bajaj, 207542
VALIDATION OF THE BAVENO CRITERIA FOR ENDOSCOPIC SURVEILLANCE OF VARICES IN CHOLESTASIC DISEASES
EASL LiverTree™, STEPHANIE TASAYCO, 207543
Decreased Model for End-Stage Liver Disease (MELD) score after antiviral treatment predicts reduced risk of mortality and hepatic events in chronic hepatitis B related cirrhosis - a study of 1,729 subjects
EASL LiverTree™, Grace LH Wong, 207556
Propranolol Treatment Associated with Better Survival and Reduced Sepsis in Cirrhotic Patients with Hepatic Encephalopathy
EASL LiverTree™, Pei Chang Lee, 207557
Six-minute Walk Test and Sarcopenia in Predicting Mortality in Patients with Cirrhosis
EASL LiverTree™, ThucNhi Dang, 207558
The effect of primary prophylaxis therapy for large esophageal varices in patients with hepatocellular carcinoma 
EASL LiverTree™, Hsiao Sheng Lu, 207559
TIPS placement improves sarcopenia and modifies fat distribution: a monocentric retrospective study 
EASL LiverTree™, Florent Artru, 207574
Increasing Burden of Hepatic Encephalopathy among Hospitalized Adults, With Significantly Higher Risk of In-Hospital Mortality in African Americans: An Analysis of the 2007-2013 Nationwide Inpatient Sample
EASL LiverTree™, Grishma Hirode, 207575
Health care costs are double for non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH) patients with compensated cirrhosis (CC) who progress to end-stage liver disease (ESLD)
EASL LiverTree™, Rohit Loomba, 207576
High real-world healthcare costs in non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH) compensated cirrhosis (CC)patients with and without type-2 diabetes mellitus (DM): A large German database study
EASL LiverTree™, Ali Canbay, 207577
RELATIONSHIP BETWEEN VISCERAL FAT AND PORTAL VEIN THROMBOSIS IN PATIENTS WITH LIVER CIRRHOSIS
EASL LiverTree™, Marta Hernandez Conde, 207592
Terlipressin for variceal bleeding induces severe plasma sodium disturbances in non-cirrhotic portal hypertension
EASL LiverTree™, Peter Lykke Eriksen, 207593
Outcome after the use of SX-ELLA Danis bleeding stents for refractory variceal bleeding- a Vienna Multicenter Experience
EASL LiverTree™, Nikolaus Pfisterer, 207594
The beneficial effects of non-selective betabockers in secondary prophylaxis are most pronounced in patients without refractory ascites
EASL LiverTree™, Nikolaus Pfisterer, 207595
Tolerability and Kinetics of SYNB1020 in a Phase 1, First-in-Human, Healthy Adult Volunteer Study
EASL LiverTree™, Marja Puurunen, 207610
Cardiac fibrosis and coronary atherosclerosis in cirrhosis. Indications of cirrhotic cardiomyopathy?
EASL LiverTree™, Signe Wiese, 207611
The role of bile acids in the development of structural myocardial changes and cardiac dysfunction in patients with cirrhosis
EASL LiverTree™, Signe Wiese, 207612
Hepatopulmonary syndrome: a spontaneously reversible condition? Variability in prevalence in a prospective follow-up study of cirrhotic patients
EASL LiverTree™, Aurelia Chiricuta, 207613
Eradication of hepatitis C virus (HCV) in patients with decompensated cirrhosis does not improve the management of ascites after one year of follow-up.
EASL LiverTree™, Adrià Juanola Mayos, 207627
Gender differences regarding sarcopenia development in  chronic liver disease
EASL LiverTree™, Atsushi Hiraoka, 207628
Assessment of subclinical hepatic encephalopathy by using EncephalApp Stroop test and brain MRI
EASL LiverTree™, Maria C. Speranta Iacob, 207629
Impact of antibiotic prophylaxis of spontaneous bacterial peritonitis on colonization and infections with multidrug-resistant bacteria
EASL LiverTree™, Marcus Maximilian Mücke, 207630
Sustained Long-term Improvement in Clinical and Cognitive Outcomes after Fecal Microbiota Transplantation in Cirrhosis
EASL LiverTree™, Jasmohan S Bajaj, 207646
High Mortality Rate in HBV-related Cirrhosis Patients with HEV Superinfection
EASL LiverTree™, Tai-Chung Tseng, 207647
Clinical features and outcomes of hepatitis E in patients with underlying chronic liver disease: a respective case-control study
EASL LiverTree™, Yijin Wang, 207648
Risk factors of hepatitis E related liver failure: a restrospective case-control study
EASL LiverTree™, Yijin Wang, 207649
Rolling circle amplification and nanopore-based deep sequencing of full-length HBV genomes
EASL LiverTree™, Philippa Matthews, 207664
LTPprodrug technology offers new generation nucleotide antiviral agents 
EASL LiverTree™, Lin Zhi, 207665
Conservation and variation of the hepatitis E virus open reading frame 2 proteome
EASL LiverTree™, Shaoshi Zhang, 207666
Mutations in HCV NS3 but no Sec14L2 variants alter HCV RNA replication of natural occuring viruses in cell culture
EASL LiverTree™, Sandra Ciesek, 207667
HBV reactivation and changes in interferon-stimulated gene expression during treatment of direct-acting antivirals for HCV: Analyses in a novel in vitro model for HBV-HCV coinfection using human induced pluripotent stem cell-derived hepatic cells
EASL LiverTree™, Yasuhiro Asahina, 207681
Post transcriptional regulation of Hepatitis B virus in a prospective cohort of chronically infected patients
EASL LiverTree™, Aurélie Schnuriger, 207682
Murine hepatocytes with humanized sodium taurocholat polypeptide (NTCP) limit HDV infection in vivo independent of adaptive immune responses
EASL LiverTree™, Marc Luetgehmann, 207684
Pro-fibrogenic mediator Osteopontin is intimately involved in Chronic Hepatitis B and promotes cccDNA production
EASL LiverTree™, Sandra Phillips, 207698
Whole Genome Viral Sequencing Reveals Subgenotype Specific Dynamics of Antiviral Treatment Response in HBeAg Positive and Treatment Naive Chronic Hepatitis B Patients
EASL LiverTree™, Ondrej Podlaha, 207699
Control of glycokinase activity by the HCV protein NS5A increases lipogenesis
EASL LiverTree™, Olivier Diaz, 207700
Evolution and persistence of resistance-associated substitutions of hepatitis c virus after daclatasvir plus asunaprevir treatment failures
EASL LiverTree™, Yechan Jeong, 207701
HCV induced-miR-21 activation triggers lipid accumulation and promotes viral replication
EASL LiverTree™, Sophie Clément, 207716
Hepatitis E virus replication and interferonresponse in human placental-derived cells
EASL LiverTree™, Patrick Behrendt, 207717
Are there different profiles in microRNA expression in HBV/HDV co-infected patients reflecting plasma HBsAg and HBcrAg concentrations?
EASL LiverTree™, Ivana Carey, 207718
Dimerization:  A  structural feature for the protection of Hepatitis E virus capsid protein against trypsinization
EASL LiverTree™, Wenjuan Wei, 207719
Outcome of anti-viral immunity in the liver is shaped by the level of antigen expressed in infected hepatocytes
EASL LiverTree™, Katrin Manske, 207735
The RNA genome of hepatitis E virus robustly triggers antiviral interferon response
EASL LiverTree™, Wenshi Wang, 207736
Preclinical mechanistic and efficacy evaluation of a novel small molecule TLR7 agonist RO7020531 for the treatment of chronic hepatitis B
EASL LiverTree™, Lu Gao, 207753
A systematic comparison reveals dynamic differences in early adaptive immune responses of acute-resolving versus chronic HBV replication
EASL LiverTree™, Qin Wang, 207754
Alcoholic Liver Disease replaces HCV Infection as the Leading Indication for Liver Transplantation in the United States 
EASL LiverTree™, George Cholankeril, 207755
Individualized prediction of the risk of liver-related death in patients with alcoholic cirrhosis
EASL LiverTree™, Astrid Marot, 207756
Collagen proportionate área is an independent predictor of long term outcome in patients with alcoholic liver disease
EASL LiverTree™, Marta Guerrero-Misas, 207770
Hepatoprotective Biomarkers, Amphiregulin and Soluble Fas, IncreaseDuring ELAD Treatment in Alcoholic Hepatitis Subjects
EASL LiverTree™, Jason Lapetoda, 207771
The use of proton pump inhibitors among patients with alcoholic cirrhosis is not related with increased risk of death
EASL LiverTree™, Ulrich Bang, 207772
miRNA regulation of macrophage M1/M2 polarization of Kupffer cells and PBMCs in alcoholic liver disease
EASL LiverTree™, Adam Kim, 207773
Histological severity is related to cardiovascular events in lean but not in overweight and obese subjects with NAFLD
EASL LiverTree™, Alexandra Feldman, 207789
Characterization of Patients with Both Alcoholic and Nonalcoholic Fatty Liver Disease (BAFLD) in a Large United States Cohort
EASL LiverTree™, Naim Alkhouri, 207790
Increased gut permeability is associated with oxidative stress in patients with NAFLD
EASL LiverTree™, Francesco Baratta, 207791
The Platelet Count is Declining in American Adults in Parallel with an Increase in Risk Factors for Nonalcoholic Fatty Liver Disease
EASL LiverTree™, Amandeep Singh, 207805
The relationship between NAFLD and breast cancer: High prevalence and poor prognosis.
EASL LiverTree™, Young-Sun Lee, 207807
Impact of duodenal-jejunal bypass liner on non-alcoholic fatty liver disease
EASL LiverTree™, Thomas Karlas, 207808
Nonalcoholic fatty liver disease in the first trimester and subsequent development of gestational diabetes: A prospective cohort study
EASL LiverTree™, Won Kim, 207809
Saturated fat is more metabolically harmful for the human liver than polyunsaturated fat or simple sugars
EASL LiverTree™, Panu Luukkonen, 207822
Low-moderate alcohol use is associated with a  lower prevalence of non-alcoholic fatty liver disease in Hispanics/Latinos living in the US:  Results from the Hispanic Community Health Study/Study of Latinos (HCHS/SOL)
EASL LiverTree™, Aynur Unalp-Arida, 207823
Even modest alcohol use is associated with greater steatosis on magnetic resonance imaging in patients with NAFLD - a pilot study
EASL LiverTree™, Veeral Ajmera, 207824
Role of nutritional intake on clinical presentation of lean and overweight NAFLD
EASL LiverTree™, Rosa Lombardi, 207825

Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.


Save Settings